Ocular Therapeutix (OCUL) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
May 9, 2022 4:01 PM EDTDEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Quarterly Net Product Revenue of $12.5 Million, Representing Year-Over-Year Growth of 87%
Guiding DEXTENZA Annual Net Product Revenue for 2022 between $55 to $60 million, Representing Annual Growth of Approximately 26% to 38%
Expanding Commercial Team to Address the Commercial Opportunity for DEXTENZA in the Office Setting
Topline Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD Anticipated in the Third Quarter of 2022
Dosing of Subjects in Phase 2 OTX-TIC Clinical Trial for the... More
